Bright Minds Biosciences Inc Quick Ratio (DRUG) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Bright Minds Biosciences Inc   (NASDAQ: DRUG)

Bright Minds Biosciences Inc 's Quick Ratio

DRUG's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 35.59 above company average Quick Ratio.

Within Major Pharmaceutical Preparations industry 15 other companies have achieved higher Quick Ratio than Bright Minds Biosciences Inc in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 0 to 97.

Explain Quick Ratio?
How much Cash & cash equivalents DRUG´s has?
What are DRUG´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DRUG Quick Ratio (Sep 30 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Sep 30 2024)
Q4
Y / Y Current Liabilities Change 341.7 % 341.7 % 341.7 % 341.7 % 88.28 %
Y / Y Cash & cash equivalent Change 1340.45 % 1340.45 % 1340.45 % 1340.45 % -14.95 %
Quick Ratio MRQ 35.59 35.59 35.59 35.59 10.91
DRUG's Total Ranking # 97 # 0 # # #
Seq. Current Liabilities Change 0 % 0 % 0 % 341.7 % 0 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % 1340.45 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 16
Healthcare Sector # 22
Overall Market # 97


Quick Ratio Statistics
High Average Low
35.59 19.66 7.97
(Sep 30 2025)   (Sep 30 2022)




Financial Statements
Bright Minds Biosciences Inc 's Current Liabilities $ 2 Millions Visit DRUG's Balance sheet
Bright Minds Biosciences Inc 's Cash & cash equivalent $ 64 Millions Visit DRUG's Balance sheet
Source of DRUG's Sales Visit DRUG's Sales by Geography


Cumulative Bright Minds Biosciences Inc 's Quick Ratio

DRUG's Quick Ratio for the trailling 12 Months

DRUG Quick Ratio

 (Sep 30 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Sep 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth 341.7 % 303.59 % 253.8 % 186 % 88.28 %
Y / Y Cash & cash equivalent TTM Growth 1340.45 % 958.79 % 607.98 % 284.42 % -14.95 %
Quick Ratio TTM 35.59 33.86 31.04 25.61 10.91
Total Ranking TTM # 2411 # 0 # # #
Seq. Current Liabilities TTM Growth 23.98 % 31.54 % 46.07 % 85.43 % 13.28 %
Seq. Cash & cash equivalent TTM Growth 30.32 % 43.51 % 77.02 % 335.11 % -4.21 %

Quick ratio ranking by company, industry and sector >> Back to DRUG Financial Strength Comparisons >> Go to Compare DRUG Quick Ratio to its Competitors

On the trailing twelve months basis DRUG Cash & cash equivalent more than doubled by 1340.45 % in Q4 2025 year on year, faster than Current Liabilities, this led to increase in in Bright Minds Biosciences Inc 's Quick Ratio to 35.59, above DRUG average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 408 other companies have achieved higher Quick Ratio than Bright Minds Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 0 to 2411.

Explain Quick Ratio?
How much Cash & cash equivalents DRUG´s has?
What are DRUG´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 409
Healthcare Sector # 811
Within the Market # 2411


trailing twelve months Quick Ratio Statistics
High Average Low
24.16 11.91 5.98
(Sep 30 2023)   0




Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2025 MRQ Cash & cash equivalentSep 30 2025 MRQ Current Liabilities
Mira Pharmaceuticals Inc   89.79 $ 7.536  Millions$ 0.084  Millions
Gh Research Plc  65.06 $ 249.654  Millions$ 3.837  Millions
Lb Pharmaceuticals Inc  53.15 $ 314.479  Millions$ 5.917  Millions
Benitec Biopharma Inc   50.23 $ 94.534  Millions$ 1.882  Millions
Monopar Therapeutics Inc   49.71 $ 127.677  Millions$ 2.569  Millions
Curanex Pharmaceuticals Inc  46.70 $ 5.831  Millions$ 0.125  Millions
Altimmune inc   43.88 $ 210.776  Millions$ 4.804  Millions
Xbiotech Inc   41.34 $ 147.367  Millions$ 3.565  Millions
Belite Bio Inc  36.61 $ 352.932  Millions$ 9.641  Millions
Rapport Therapeutics Inc   35.84 $ 513.026  Millions$ 14.316  Millions
Bright Minds Biosciences Inc   35.59 $ 63.669  Millions$ 1.789  Millions
Janux Therapeutics Inc   35.54 $ 988.993  Millions$ 27.831  Millions
Inhibitor Therapeutics Inc   34.01 $ 2.977  Millions$ 0.088  Millions
Disc Medicine Inc   33.50 $ 615.920  Millions$ 18.383  Millions
Roivant Sciences Ltd   32.77 $ 4,385.835  Millions$ 133.857  Millions
Mbx Biosciences Inc   32.47 $ 391.673  Millions$ 12.062  Millions
Upstream Bio Inc   31.28 $ 372.427  Millions$ 11.908  Millions
Repare Therapeutics Inc   30.54 $ 112.604  Millions$ 3.687  Millions
Keros Therapeutics Inc   28.78 $ 693.472  Millions$ 24.092  Millions
Contineum Therapeutics Inc   28.68 $ 182.407  Millions$ 6.361  Millions
Viking Therapeutics Inc   27.88 $ 714.570  Millions$ 25.630  Millions
Liquidia Corporation  26.17 $ 157.496  Millions$ 6.019  Millions
Edgewise Therapeutics inc   26.03 $ 563.340  Millions$ 21.646  Millions
Prothena Corporation Public Limited Company  25.09 $ 330.843  Millions$ 13.188  Millions
Immuneering Corporation  24.83 $ 227.563  Millions$ 9.164  Millions
Psyence Biomedical ltd   23.53 $ 7.150  Millions$ 0.304  Millions
Lava Therapeutics Nv  23.48 $ 99.364  Millions$ 4.231  Millions
Trevi Therapeutics Inc   22.29 $ 194.927  Millions$ 8.745  Millions
Ligand Pharmaceuticals Incorporated  21.76 $ 664.522  Millions$ 30.539  Millions
Aprea Therapeutics Inc   21.39 $ 13.718  Millions$ 0.641  Millions

Date modified: 2026-07-07T10:24:00+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.